613 related articles for article (PubMed ID: 19287306)
1. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
2. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
3. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
Ohnishi T; Kanoh T; Tono T; Danno K; Watanabe A; Nakamura H; Tsukao Y; Inatome J; Kim T; Kagara N; Taniguchi H; Kimura Y; Nakano Y; Monden T; Imaoka S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2554-6. PubMed ID: 21224637
[TBL] [Abstract][Full Text] [Related]
14. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
15. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
[TBL] [Abstract][Full Text] [Related]
16. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Guthoff I; Lotspeich E; Fester C; Wallin I; Schatz M; Ehrsson H; Kornmann M
Anticancer Res; 2003; 23(6D):5203-8. PubMed ID: 14981990
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
19. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
